Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.
Yongjun LiMingming YangXi ChenRui ZhangJing LiXiaoguo ZhangPengfei ZuoGenshan MaPublished in: Journal of interventional cardiology (2022)
After 1 year of PCSK9 inhibition treatment for ACS patients, the area stenosis of non-TLR was considerably reduced.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- cardiovascular disease
- antiplatelet therapy
- heart failure
- immune response
- patient reported outcomes
- st segment elevation myocardial infarction
- aortic stenosis